NewsRx

Search our medical news database

Head and Neck Cancer

Targeted Therapy Improves Survival Rates Among Patients With Head and Neck Cancer

Published in Law and Health Weekly, September 15th, 2007

Research and Markets has announced the addition of European Head and Neck Cancer Therapeutics Markets to their offering.

This research service titled European Head and Neck Cancer Therapeutics Markets provides market drivers, restraints and revenue forecasts for this market. In this research, Frost & Sullivan's expert analysts thoroughly examine the chemotherapy and targeted therapies markets. Targeted Therapy Improves Survival Rates among Patients with Head and Neck Cancer.

Physicians in Europe are eager for novel therapies for head and neck cancer, as five-year survival rates among patients have...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook